David L. Lacey - 15 May 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Reporting relationship: Director
Issuer ticker: NRIX
Reported as of: 15 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 May 2026, 17:51:31 UTC
Prior SEC filing: 12 Jun 2025
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel Burbach, as Attorney-in-Fact for David L. Lacey

Key filing fact

David L. Lacey filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 15 May 2026.

Key facts

This page summarizes David L. Lacey's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 May 2026, 17:51.

Change

Previous filing in this sequence was filed on 12 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001734422 Primary reporting owner

Lacey David L.

Relationship: Director
Address: C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE
Signature: /s/ Daniel Burbach, as Attorney-in-Fact for David L. Lacey
Signature date: 15 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRIX transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value
Shares: +31,250
Change %
Price: $0.000000^*
Shares after: 31,250
Date: 15 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 31,250
Exercise price: $15.86
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.